The latest research news in genetics and genomics.
The company reported total revenues of $1.31 million, up from $922,000 in Q4 2018, and 3,854 OVA1 sales, up 93 percent from 1,996 a year ago.
The firm is planning a prospective trial for the test after results in a small retrospective study showed good performance in identifying cancers and precancers.
The consortium is developing a real-time PCR test for host detection assays targeting epigenetic signatures and viral RNA for early-stage monitoring of potentially infected individuals.
Launched by 454 Founder Jonathan Rothberg and backed by $150 million in funding, the firm is the latest of several outfits to pursue protein sequencing.
The findings suggest blood-based testing for tau brain deposits is feasible and could be combined with other blood-based assays to improve Alzheimer's testing.
